Edition:
United States

AstraZeneca PLC (AZN)

AZN on New York Consolidated

29.08USD
17 Aug 2017
Change (% chg)

$0.00 (+0.00%)
Prev Close
$29.08
Open
--
Day's High
--
Day's Low
--
Volume
13,600
Avg. Vol
4,676,416
52-wk High
$35.60
52-wk Low
$25.55

Latest Key Developments (Source: Significant Developments)

AstraZeneca hires two immuno-oncology experts
Monday, 31 Jul 2017 08:30am EDT 

July 31 (Reuters) - AstraZeneca Plc ::‍Jean-Charles Soria joins Medimmune, co's global biologics research and development arm, as senior vice president, head of oncology innovative medicines.Geoffrey Kim appointed head oncology strategic combinations at AstraZeneca​.  Full Article

CEO believes AstraZeneca can continue to secure dividend
Thursday, 27 Jul 2017 09:26am EDT 

July 27 (Reuters) - AstraZeneca CEO Pascal Soriot tells analysts::Believes company can continue to secure the dividend.  Full Article

Roche says real demand, not stocking, drives Ocrevus sales
Thursday, 27 Jul 2017 08:30am EDT 

July 27 (Reuters) - Roche Holding AG :Roche ceo says no doubt perjeta will be a substantial growth driver.Roche drugs head says astrazeneca lung cancer study failure doesn't change roche's plans.Roche drugs head says sees no risk to regulatory approvals from aphinity study.Roche drugs head says ocrevus sales reflect demand, not major stocking.Roche ceo says bullish about cancer immunotherapy, want to play leading role.  Full Article

AstraZeneca's lung cancer drug succeeds late-stage trial
Thursday, 27 Jul 2017 07:23am EDT 

July 27 (Reuters) - Astrazeneca Plc -:Tagrisso® (osimertinib) significantly improves progression-free survival in the phase iii flaura trial for lung cancer.Astrazeneca plc - ‍tagrisso met primary endpoint​.  Full Article

Valeant announces U.S. launch of siliq injection
Thursday, 27 Jul 2017 07:22am EDT 

July 27 (Reuters) - Astrazeneca Plc ::Valeant announces U.S. launch of siliq (brodalumab) injection.Valeant says that its dermatology unit will be renamed Ortho Dermatologics, effective immediately.Valeant says under new senior leadership team lead by Bill Humphries, executive vice president and company group chairman, Ortho Dermatologics.Valeant - ‍siliq has a black box warning for "risks of suicidal ideation and behavior​".  Full Article

AstraZeneca CEO: proud to lead AZ, no comment on rumours of move to Teva
Thursday, 27 Jul 2017 03:23am EDT 

July 27 (Reuters) - AstraZeneca CEO Pascal Soriot tells reporters::Not commenting on speculation about his position but proud to be CEO of AZ.Looks forward to continuing to lead AZ team.Nothing further to add, following rumours he might be leaving to join Teva.Further company coverage: AZN.L.  Full Article

Astrazeneca says establish strategic oncology collaboration with Merck
Thursday, 27 Jul 2017 02:06am EDT 

July 27 (Reuters) - Astrazeneca Plc ::ASTRAZENECA AND MERCK ESTABLISH STRATEGIC ONCOLOGY COLLABORATION.ASTRAZENECA PLC - ASTRAZENECA AND MERCK WILL INDEPENDENTLY DEVELOP AND COMMERCIALISE LYNPARZA AND POTENTIAL MEDICINE SELUMETINIB IN COMBINATIONS WITH COMPANIES' RESPECTIVE.MERCK WILL PAY CO UP TO $8.5 BILLION IN TOTAL CONSIDERATION.ASTRAZENECA- COS TO SHARE DEVELOPMENT, COMMERCIALISATION COSTS FOR LYNPARZA, SELUMETINIB MONOTHERAPY, NON-PD-L1/PD-1 COMBINATION THERAPY OPPORTUNITIES.ASTRAZENECA PLC - MERCK WILL FUND ALL DEVELOPMENT AND COMMERCIALISATION COSTS OF KEYTRUDA IN COMBINATION WITH LYNPARZA OR SELUMETINIB.ASTRAZENECA PLC - ASTRAZENECA WILL FUND ALL DEVELOPMENT AND COMMERCIALISATION COSTS OF IMFINZI IN COMBINATION WITH LYNPARZA OR SELUMETINIB.ASTRAZENECA PLC - ASTRAZENECA WILL CONTINUE TO MANUFACTURE LYNPARZA AND SELUMETINIB.UNDER TERMS OF AGREEMENT, ASTRAZENECA ANTICIPATES APPROXIMATELY $1 BILLION TO BE RECORDED UNDER EXTERNALISATION REVENUE IN 2017.COLLABORATION AGREEMENT WAS COMPLETED UPON SIGNING ON 26 JULY 2017.ASTRAZENECA PLC - MERCK WILL PAY ASTRAZENECA UP TO $8.5 BILLION IN TOTAL CONSIDERATION.  Full Article

Astrazeneca says Faslodex receives EU approval as first-line therapy for advanced breast cancer
Wednesday, 26 Jul 2017 11:46am EDT 

July 26 (Reuters) - ASTRAZENECA PLC ::EUROPEAN COMMISSION APPROVED FASLODEX.SAFETY, TOLERABILITY PROFILES FOR FASLODEX, ANASTROZOLE REPORTED IN FALCON TRIAL WERE IN LINE WITH CURRENT EXPERIENCE.MOST-COMMONLY REPORTED ADVERSE EVENTS IN FASLODEX AND ANASTROZOLE ARMS WERE ARTHRALGIA, HOT FLUSH AND NAUSEA.  Full Article

Astrazeneca says Kyntheum approved in EU for treatment of adults with plaque psoriasis
Thursday, 20 Jul 2017 03:10am EDT 

July 20 (Reuters) - Astrazeneca Plc ::Kyntheum approved in EU for treatment of adults with moderate-to-severe plaque psoriasis.  Full Article

AstraZeneca CEO said to plan on staying at drugmaker - StreetInsider citing Bloomberg
Friday, 14 Jul 2017 02:17pm EDT 

July 14 (Reuters) - :AstraZeneca CEO said to plan on staying at drugmaker - StreetInsider citing Bloomberg.  Full Article

Photo

FDA expands use of AstraZeneca/Merck ovarian cancer drug

The U.S. Food and Drug Administration on Thursday expanded the use of Lynparza, sold by AstraZeneca Plc and Merck & Co Inc, to include ongoing treatment of patients with recurrent ovarian cancer who have responded to platinum-based chemotherapy.